A- A A+

Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose. 

Krieter P, Gyaw S, Chiang CN, Crystal R, Skolnick P.  

J Clin Pharmacol. 2019;59(7):947-957. doi:10.1002/jcph.1384


Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial. 

Kosten T, Aharonovich E, Nangia N, et al. 

Addict Behav. 2020;111:106538. doi:10.1016/j.addbeh.2020.106538


Letter To The Editor - Drug Eruption After Sustained Release Naltrexone Pellet Implantation -- Editöre Mektup - Yavaş Salınımlı Naltrekson İmplant Uygulaması Sonrası Gelişen İlaç Erüpsiyonu.

Ak S, Can Gürel Ş. 

Turk Psikiyatri Derg. 2020;31(2):146-147. 


Potential uses of naltrexone in emergency department patients with opioid use disorder. 

Bradley ES, Liss D, Carreiro SP, Brush DE, Babu K. 

Clin Toxicol (Phila). 2019;57(9):753-759. doi:10.1080/15563650.2019.1583342


USA. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Full Document.

This updated Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. (SAMHSA - Substance Abuse & Mental Health Services Administration, USA, Mai 2020)


Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.

Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM.

JAMA Netw Open. 2020 Feb 5;3(2):e1920622. doi: 10.1001/jamanetworkopen.2019.20622.


Naltrexone use in pregnancy: a time for change.

Caritis SN, Venkataramanan R.

Am J Obstet Gynecol. 2020 Jan;222(1):1-2. doi: 10.1016/j.ajog.2019.08.041. 


A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.

Sullivan MA, Bisaga A, Pavlicova M, Carpenter KM, Choi CJ, Mishlen K, Levin FR, Mariani JJ, Nunes EV.

Am J Psychiatry. 2019 Feb 1;176(2):129-137. doi: 10.1176/appi.ajp.2018.17070732. 


Acceptability and efficacy of naltrexone for criminal justice‐involved individuals with opioid use disorder: a systematic review and meta‐analysis.

Bahji, A., Carlone, D., and Altomare, J. ( 2019) 

Addiction, doi.org/10.1111/add.14946.



Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.

Friedmann PD, Wilson D, Hoskinson R Jr, Poshkus M, Clarke JG.

J Subst Abuse Treat. 2018 Feb;85:45-48. doi: 10.1016/j.jsat.2017.04.010. 


Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.

Velasquez M, Flannery M, Badolato R, Vittitow A, McDonald RD, Tofighi B, Garment AR, Giftos J, Lee JD.

Addict Sci Clin Pract. 2019 Oct 1;14(1):37. doi: 10.1186/s13722-019-0166


Rizmoic / Nalmedine 200 Mikrogramm Filmtabletten - ZUSAMMENFASSUNG DER MERKMALE DES ARZNEIMITTELS

Rizmoic wird angewendet zur Behandlung von Opioid-induzierter Obstipation (OIC, opioid-induced constipation) bei Erwachsenen, die früher bereits mit einem Abführmittel behandelt wurden. (Europäische Arzneimittel-Agentur, 2019)


A Review of Samidorphan: A Novel Opioid Antagonist.

Chaudhary AMD, Khan MF, Dhillon SS, Naveed S.

Cureus. 2019 Jul 15;11(7):e5139. doi: 10.7759/cureus.5139. Review.


Letter to the Editor: Response to Darke S, et al. Circumstances of death of opioid users being treated with naltrexone. 

Streel, E., and Brewer, C. ( 2019)

Addiction, First published: 16 September 2019, doi.org/10.1111/add.14826


Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.

Nunes EV, Bisaga A, Krupitsky E, Nangia N, Silverman BL, Akerman SC, Sullivan MA.

Addiction. 2019 Jul 17. doi: 10.1111/add.14735.



Circumstances of death of opioid users being treated with naltrexone.

Darke S, Farrell M, Duflou J, Larance B, Lappin J.

Addiction. 2019 Jul 6. doi: 10.1111/add.14729. 



Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.

Wachman EM, Saia K, Miller M, Valle E, Shrestha H, Carter G, Werler M, Jones H.

Clin Ther. 2019 Jul 27. pii: S0149-2918(19)30346-7. doi: 10.1016/j.clinthera.2019.07.003.



Opiate Antagonists Do Not Interfere With the Clinical Benefits of Stimulants in ADHD: A Double-Blind, Placebo-Controlled Trial of the Mixed Opioid Receptor Antagonist Naltrexone.

Spencer TJ, Bhide P, Zhu J, Faraone SV, Fitzgerald M, Yule AM, Uchida M, Spencer AE, Hall AM, Koster AJ, Biederman J.

J Clin Psychiatry. 2018 Jan/Feb;79(1). pii: 16m11012. doi: 10.4088/JCP.16m11012.


Implementing an Opioid Risk Reduction Program in the Acute Comprehensive Inpatient Rehabilitation Setting.

Van SP, Yao AL, Tang T, Kott M, Noles A, Dabai N, Coslick A, Rojhani S, Sprankle LA, Hoyer EH.

Arch Phys Med Rehabil. 2019 May 20. pii: S0003-9993(19)30307-7. doi: 10.1016/j.apmr.2019.04.011.



Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.

Springer SA, Di Paola A, Azar MM, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL.

J Acquir Immune Defic Syndr. 2018 May 1;78(1):43-53. doi: 10.1097/QAI.0000000000001634.


Naltrexone-associated Visual Hallucinations: A Case Report.

Lee DB, Woo YS, Bahk WM.

Clin Psychopharmacol Neurosci. 2019 May 31;17(2):329-331. doi: 10.9758/cpn.2019.17.2.329.


Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose.

Krieter P, Gyaw S, Crystal R, Skolnick P.

J Pharmacol Exp Ther. 2019 Apr 2. pii: jpet.118.256115. doi: 10.1124/jpet.118.256115.


Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report.

Ward HB, Barnett BS, Suzuki J.

Subst Abus. 2019 Mar 19:1-6. doi: 10.1080/08897077.2019.1573776.



Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial.

Krupitsky E, Blokhina E, Zvartau E, Verbitskaya E, Lioznov D, Yaroslavtseva T, Palatkin V, Vetrova M, Bushara N, Burakov A, Masalov D, Mamontova O, Langleben D, Poole S, Gross R, Woody G.

Lancet HIV. 2019 Mar 14. pii: S2352-3018(18)30362-X. doi: 10.1016/S2352-3018(18)30362-X. 

(Registrierung erforderlich)


Naltrexone: A History and Future Directions.

Srivastava B, Gold MS.

Cerebrum. 2018 Sep 1;2018. pii: cer-13-18.


No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study.

Latif ZE, Solli KK, Opheim A, Kunoe N, Benth JŠ, Krajci P, Sharma-Haase K, Tanum L.

Am J Addict. 2019 Jan 31. doi: 10.1111/ajad.12859. 



Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis

Monica Bolton, Alex Hodkinson, Shivani Boda, Alan Mould, Maria Panagioti, Sarah Rhodes, Lisa Riste and Harm van Marwijk

BMC Medicine2019, 17:10, doi.org/10.1186/s12916-018-1242-0


Drug combo shows promise in treatment of depression and addiction

The combination of naltrexone and ketamine can help treat both symptoms of addiction and depression, a preliminary study by Yale University researchers suggests. (Yale News, USA, 09.01.2019)



Singh D, Saadabadi A.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.2018 Nov 27., PMID: 30521232


Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study. 

Latif Z, Šaltytė Benth J, Solli KK, et al. 

JAMA Psychiatry.Published online December 19, 2018. doi:10.1001/jamapsychiatry.2018.3537